NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 FINAL #1 MICE Facility: Southern Research Institute Chemical CAS #: 693-13-0 Lock Date: 03/14/03 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Natural Death 5 5 6 4 Moribund Sacrifice 12 11 4 5 Accidently Killed 1 1 1 Survivors Terminal Sacrifice 33 32 38 40 Natural Death 1 Moribund Sacrifice 1 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Esophagus (50) (50) (49) (50) Gallbladder (42) (47) (42) (47) Intestine Large, Colon (49) (48) (48) (48) Intestine Large, Cecum (46) (45) (44) (47) Intestine Small, Duodenum (46) (46) (44) (47) Adenoma 1 (2%) Intestine Small, Jejunum (47) (45) (44) (46) Adenoma 1 (2%) Carcinoma 1 (2%) 1 (2%) Intestine Small, Ileum (46) (44) (45) (47) Liver (50) (50) (50) (50) Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%) Hepatocellular Carcinoma 8 (16%) 2 (4%) 7 (14%) 3 (6%) Hepatocellular Carcinoma, Multiple 2 (4%) 1 (2%) Hepatocellular Adenoma 13 (26%) 16 (32%) 10 (20%) 9 (18%) Hepatocellular Adenoma, Multiple 8 (16%) 11 (22%) 11 (22%) 9 (18%) Hepatocholangiocarcinoma, Multiple 1 (2%) Histiocytic Sarcoma 3 (6%) 2 (4%) 1 (2%) Liposarcoma, Metastatic, Tissue NOS 1 (2%) Mesentery (23) (20) (14) (18) Hemangiosarcoma, Metastatic, Liver 1 (6%) Histiocytic Sarcoma 1 (4%) 2 (14%) 2 (11%) Liposarcoma 1 (6%) Pancreas (50) (48) (50) (50) Histiocytic Sarcoma 1 (2%) 1 (2%) Salivary Glands (50) (50) (50) (49) Page 2 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Stomach, Forestomach (50) (49) (50) (50) Squamous Cell Carcinoma 1 (2%) Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%) 2 (4%) Stomach, Glandular (49) (48) (47) (50) Tooth (1) (1) (1) (2) Peridontal Tissue, Histiocytic Sarcoma, Metastatic, Uncertain Primary Site 1 (100%) Peridontal Tissue, Histiocytic Sarcoma, Metastatic, Nose 1 (50%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (49) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (50) (49) (50) Histiocytic Sarcoma 1 (2%) 1 (2%) Subcapsular, Adenoma 1 (2%) Adrenal Medulla (49) (50) (49) (49) Histiocytic Sarcoma 1 (2%) Pheochromocytoma Benign 1 (2%) 1 (2%) Islets, Pancreatic (50) (49) (50) (50) Adenoma 2 (4%) Pituitary Gland (48) (50) (50) (46) Pars Distalis, Adenoma 4 (8%) 12 (24%) 3 (6%) 10 (22%) Pars Distalis, Carcinoma 1 (2%) Pars Intermedia, Adenoma 2 (4%) 1 (2%) 1 (2%) Thyroid Gland (50) (50) (50) (50) Bilateral, Follicular Cell, Adenoma 1 (2%) Follicular Cell, Adenoma 2 (4%) 2 (4%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Tissue NOS (5) (8) (3) (4) Abdominal, Pelvic, Liposarcoma 1 (13%) Mediastinum, Hepatocholangiocarcinoma, Metastatic, Liver 1 (25%) Page 3 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM - cont Mediastinum, Histiocytic Sarcoma 1 (20%) 1 (33%) Thoracic, Hepatocholangiocarcinoma, Metastatic, Liver 1 (25%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (49) (50) (49) (49) Cystadenoma 1 (2%) 2 (4%) 2 (4%) 2 (4%) Granulosa Cell Tumor Benign 1 (2%) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) Teratoma Benign 1 (2%) Oviduct (3) (1) Uterus (50) (50) (50) (50) Adenoma 1 (2%) 1 (2%) Histiocytic Sarcoma 3 (6%) 1 (2%) 2 (4%) 2 (4%) Leiomyosarcoma 2 (4%) Endometrium, Carcinoma 1 (2%) Endometrium, Polyp Stromal 4 (8%) 2 (4%) 5 (10%) Endometrium, Sarcoma Stromal 1 (2%) Vagina (1) Histiocytic Sarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (49) (50) (50) (49) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 2 (4%) 1 (2%) Liposarcoma, Metastatic, Tissue NOS 1 (2%) Lymph Node (11) (13) (10) (10) Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (10%) Iliac, Carcinoma, Metastatic, Uterus 1 (8%) Iliac, Histiocytic Sarcoma 1 (10%) Mediastinal, Histiocytic Sarcoma 1 (9%) 1 (10%) 1 (10%) Pancreatic, Histiocytic Sarcoma 1 (10%) Pancreatic, Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach 1 (10%) Renal, Histiocytic Sarcoma 1 (10%) Lymph Node, Mandibular (47) (49) (49) (48) Carcinoma, Metastatic, Harderian Gland 1 (2%) Page 4 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - cont Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) Lymph Node, Mesenteric (47) (48) (49) (50) Hemangioma 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) Spleen (49) (49) (50) (50) Hemangiosarcoma 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) 2 (4%) 2 (4%) Thymus (46) (48) (44) (47) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (50) (50) (49) (49) Carcinoma 1 (2%) 2 (4%) Skin (50) (50) (50) (50) Basosquamous Tumor Benign 1 (2%) Squamous Cell Carcinoma 1 (2%) Site of Application, Basal Cell Adenoma 1 (2%) Subcutaneous Tissue, Fibroma 1 (2%) Subcutaneous Tissue, Fibrosarcoma 1 (2%) Subcutaneous Tissue, Hemangioma 2 (4%) 1 (2%) 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 1 (2%) Subcutaneous Tissue, Melanoma Malignant 1 (2%) 1 (2%) Subcutaneous Tissue, Squamous Cell Carcinoma 1 (2%) Subcutaneous Tissue, Site of Application, Melanoma Benign 1 (2%) Subcutaneous Tissue, Site of Application, Myxoma 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) (50) Osteosarcoma 1 (2%) Cranium, Osteosarcoma 1 (2%) Skeletal Muscle (4) (1) (1) Lipoma 1 (25%) Rhabdomyosarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ Page 5 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) Osteosarcoma, Metastatic, Bone 1 (2%) Spinal Cord (1) (3) (2) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) (50) Alveolar/Bronchiolar Adenoma 3 (6%) 2 (4%) 2 (4%) 1 (2%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%) 4 (8%) Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%) Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%) Carcinoma, Metastatic, Mammary Gland 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 4 (8%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 2 (4%) 1 (2%) Liposarcoma, Metastatic, Tissue NOS 1 (2%) Osteosarcoma, Metastatic, Uncertain Primary Site 1 (2%) Sarcoma Stromal, Metastatic, Uterus 1 (2%) Nose (50) (50) (49) (50) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (47) (48) (49) (49) Carcinoma, Metastatic, Harderian Gland 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Retrobulbar, Carcinoma, Metastatic, Harderian Gland 1 (2%) Retrobulbar, Sarcoma 1 (2%) Harderian Gland (50) (49) (50) (50) Adenoma 9 (18%) 5 (10%) 5 (10%) 3 (6%) Carcinoma 1 (2%) 4 (8%) 1 (2%) Zymbal's Gland (1) Carcinoma 1 (100%) ____________________________________________________________________________________________________________________________________ Page 6 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (49) (49) (50) (49) Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%) Ureter (1) (1) Histiocytic Sarcoma 1 (100%) Urinary Bladder (50) (50) (49) (50) Histiocytic Sarcoma 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 3 (6%) 1 (2%) 2 (4%) 2 (4%) Lymphoma Malignant 10 (20%) 9 (18%) 7 (14%) 7 (14%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 7 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 47 43 41 41 Total Primary Neoplasms 85 84 76 70 Total Animals with Benign Neoplasms 35 38 28 31 Total Benign Neoplasms 52 62 44 44 Total Animals with Malignant Neoplasms 26 19 26 18 Total Malignant Neoplasms 33 22 32 26 Total Animals with Metastatic Neoplasms 3 3 9 4 Total Metastatic Neoplasm 4 5 11 7 Total Animals with Malignant Neoplasms 1 1 Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 8 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 5 1 2 5 Natural Death 6 9 10 8 Accidently Killed 1 Survivors Terminal Sacrifice 38 40 38 36 Moribund Sacrifice 1 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Large, Cecum (46) (43) (44) (42) Leiomyoma 1 (2%) Intestine Small, Duodenum (46) (44) (44) (40) Adenoma 1 (2%) 1 (2%) 1 (2%) Carcinoma 1 (2%) Intestine Small, Jejunum (46) (43) (44) (40) Carcinoma 1 (2%) 1 (3%) Intestine Small, Ileum (46) (44) (44) (40) Carcinoma 1 (2%) Liver (50) (50) (50) (49) Cholangiocarcinoma 1 (2%) Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%) Hepatoblastoma 1 (2%) Hepatocellular Carcinoma 16 (32%) 8 (16%) 8 (16%) 8 (16%) Hepatocellular Carcinoma, Multiple 4 (8%) 7 (14%) 3 (6%) 3 (6%) Hepatocellular Adenoma 9 (18%) 15 (30%) 11 (22%) 10 (20%) Hepatocellular Adenoma, Multiple 9 (18%) 7 (14%) 8 (16%) 9 (18%) Hepatocholangiocarcinoma 1 (2%) Histiocytic Sarcoma 1 (2%) Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach 1 (2%) Mesentery (49) (49) (50) (50) Carcinoma, Metastatic, Pancreas 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) Sarcoma 1 (2%) Schwannoma Malignant, Metastatic, Uncertain Page 9 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Primary Site 1 (2%) Pancreas (49) (50) (49) (49) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Duct, Carcinoma 1 (2%) Salivary Glands (50) (50) (50) (50) Stomach, Forestomach (50) (50) (50) (50) Squamous Cell Carcinoma 1 (2%) Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%) 1 (2%) Serosa, Carcinoma, Metastatic, Pancreas 1 (2%) Stomach, Glandular (50) (47) (48) (47) Carcinoma, Metastatic, Pancreas 1 (2%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) (50) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (50) (50) (49) Adenoma 1 (2%) 1 (2%) 1 (2%) Bilateral, Subcapsular, Adenoma 1 (2%) Subcapsular, Adenoma 3 (6%) 2 (4%) 6 (12%) 4 (8%) Adrenal Medulla (49) (50) (50) (49) Pheochromocytoma Malignant 1 (2%) Pheochromocytoma Benign 1 (2%) Islets, Pancreatic (49) (50) (49) (50) Adenoma 1 (2%) 1 (2%) 1 (2%) Carcinoma 1 (2%) Pituitary Gland (48) (47) (50) (49) Pars Intermedia, Adenoma 1 (2%) Thyroid Gland (49) (50) (50) (50) Follicular Cell, Adenoma 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ Page 10 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Peritoneum (49) (49) (49) (50) Carcinoma, Metastatic, Pancreas 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Sarcoma 1 (2%) Tissue NOS (3) (2) Abdominal, Hepatocellular Carcinoma, Metastatic, Liver 1 (33%) Mediastinum, Hepatocellular Carcinoma, Metastatic, Liver 1 (33%) 1 (50%) Thoracic, Hepatocellular Carcinoma, Metastatic, Liver 1 (33%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (50) (50) (50) (50) Prostate (50) (50) (50) (50) Carcinoma 1 (2%) Seminal Vesicle (50) (50) (50) (50) Adenoma 1 (2%) Carcinoma, Metastatic, Pancreas 1 (2%) Testes (50) (50) (50) (50) Interstitial Cell, Adenoma 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (49) (50) (50) (50) Hemangiosarcoma 1 (2%) 2 (4%) Lymph Node (6) (5) (5) (4) Mediastinal, Carcinoma, Metastatic, Pancreas 1 (25%) Mediastinal, Hepatoblastoma, Metastatic, Liver 1 (17%) Mediastinal, Sarcoma, Metastatic, Uncertain Primary Site 1 (25%) Lymph Node, Mandibular (47) (48) (47) (47) Lymph Node, Mesenteric (50) (48) (49) (48) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Spleen (49) (50) (50) (47) Hemangiosarcoma 1 (2%) 2 (4%) Thymus (47) (44) (47) (46) Page 11 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - cont Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (1) (1) Carcinoma 1 (100%) Skin (50) (50) (50) (50) Subcutaneous Tissue, Fibroma 1 (2%) Subcutaneous Tissue, Fibrosarcoma 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Hepatoblastoma, Metastatic, Liver 1 (2%) Subcutaneous Tissue, Site of Application, Lymphoma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Skeletal Muscle (2) (2) (2) (5) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (20%) Carcinoma, Metastatic, Pancreas 1 (20%) Hemangiosarcoma 1 (50%) Hepatocellular Carcinoma, Metastatic, Liver 1 (50%) Rhabdomyosarcoma 1 (50%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Peripheral Nerve (1) (1) (3) Schwannoma Malignant 1 (33%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) (50) Alveolar/Bronchiolar Adenoma 6 (12%) 5 (10%) 7 (14%) 7 (14%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) Alveolar/Bronchiolar Carcinoma 2 (4%) 3 (6%) 2 (4%) 2 (4%) Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) Carcinoma, Metastatic, Mammary Gland 1 (2%) Carcinoma, Metastatic, Pancreas 1 (2%) Page 12 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - cont Cholangiocarcinoma, Metastatic, Liver 1 (2%) Hepatoblastoma, Metastatic, Liver 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 6 (12%) 4 (8%) 3 (6%) Hepatocellular Carcinoma, Metastatic, Lung 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Mediastinum, Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) Nose (49) (50) (50) (50) Carcinoma, Metastatic, Harderian Gland 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (46) (46) (47) (44) Retrobulbar, Carcinoma, Metastatic, Harderian Gland 1 (2%) Retrobulbar, Sarcoma 1 (2%) Harderian Gland (50) (50) (50) (50) Adenoma 6 (12%) 9 (18%) 10 (20%) 8 (16%) Carcinoma 2 (4%) 1 (2%) 3 (6%) Bilateral, Adenoma 3 (6%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (48) (48) (50) (48) Cholangiocarcinoma, Metastatic, Liver 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) Schwannoma Malignant, Metastatic, Uncertain Primary Site 1 (2%) Capsule, Carcinoma, Metastatic, Pancreas 1 (2%) Renal Tubule, Adenoma 1 (2%) Urinary Bladder (50) (50) (49) (50) Hemangioma 1 (2%) 1 (2%) Serosa, Hemangiosarcoma 1 (2%) Page 13 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 1 (2%) Lymphoma Malignant 2 (4%) 2 (4%) 2 (4%) 3 (6%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 14 NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04 Route: SKIN APPLICATION Time: 09:11:56 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 42 42 42 41 Total Primary Neoplasms 75 71 74 78 Total Animals with Benign Neoplasms 29 31 33 31 Total Benign Neoplasms 44 46 47 45 Total Animals with Malignant Neoplasms 27 21 22 23 Total Malignant Neoplasms 31 25 27 33 Total Animals with Metastatic Neoplasms 8 6 4 8 Total Metastatic Neoplasm 16 11 12 22 Total Animals with Malignant Neoplasms 2 Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 15 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------